-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8

Benzinga·09/10/2026 10:32:05
Listen to the news
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the price target from $7 to $8.